Neurex Corlopam Phase IV studies will examine fenoldopam/beta blocker interaction.
Executive Summary
NEUREX CORLOPAM CONCOMITANT USE STUDY WITH BETA BLOCKERS will be conducted by the company in Phase IV. Corlopam (fenoldopam mesylate) 10 mg/mL injection was approved Sept. 23 for management of severe hypertension in hospital settings. FDA has suggested that Neurex "contact the Division of Cardio-Renal Drug Products to schedule a meeting to discuss the objectives and design of the trial."